Phase I
First patient enrolled at The University of Kansas Cancer Center in expansion cohort study characterizing the safety, pharmacokinetics and pharmacodynamics of fosciclopirox in bladder cancer patients
Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota, announced the results of DAV132CL-1005, a Phase 1 clinical study which investigated the potential effect of DAV132 on the bioavailability of warfarin or clonazepam, two widely used drugs with narrow therapeutic index.
Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.
Prokarium, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization acceptance from the UK Medicines and Healthcare products Regulatory Agency to run a first-in-human Phase I trial with Entervax™, a bivalent vaccine against enteric fever.
Jonathan Cotliar, chief medical officer of Science 37, a leader in virtual clinical trials, took time to speak with BioSpace about virtual and hybrid clinical trials, the CNS Summit and Science 37.
In its announcement, Solid Biosciences said a patient in its second cohort who was dosed in October experienced a serious adverse event that was deemed related to the drug.
The drug failed to meet the primary endpoints of progression-free survival and overall response rate.
A clinical Phase II safety and efficacy trial is planned for 2020 for the treatment of influenza, an indication with a very high unmet medical need
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
Martinsried/ Munich Medigene AG announces that immune monitoring data during the first year of treatment from the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia will be presented at the upcoming ASH Annual Meeting taking place 7 - 10 December 2019 in Orlando, Florida, USA.
PRESS RELEASES